juna paw - Academia.edu (original) (raw)
Uploads
Papers by juna paw
Basal insulin analogs have been introduced into clinical practice for many years ago for diabetes... more Basal insulin analogs have been introduced into clinical practice for many years ago for diabetes management. Overall development of long-acting insulin is aimed to improve glycemic control by mimicking as close as possible to the normal insulin release and decrease patient's hypoglycemic episodes. Currently available long-acting insulin are insulin glargine 100 units (IGla 100U) and insulin detemir (IDet). However, both glargine and detemir still do not completely mimic physiological secretion.When administer high dose, their pharmacokinetic profile showed a peak concentration and a low dose may not enough to cover a 24 hours duration of action and there is still intraindividual variability. IGla 300U was a new basal insulin which was modified from IGla 100U with slow release formulation in order to overcome the unmet needs of current basal insulin. US Food and drug administration (FDA) has given marketing authorization to IGla 300U in February, 2015. IGla 300U can be used in both type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) for basal and basal-bolus therapy. It offers efficacy and safety with less pharmacodynamic variability, intraindividual variability and duration of action over 24 hours, resulting in less hypoglycemic episodes and flexible dosing regimen. In summary, IGla 300U will be an effective treatment option as basal insulin by controlling blood glucose level, offering an advantage of few hypoglycemic events and less weight gain.
Basal insulin analogs have been introduced into clinical practice for many years ago for diabetes... more Basal insulin analogs have been introduced into clinical practice for many years ago for diabetes management. Overall development of long-acting insulin is aimed to improve glycemic control by mimicking as close as possible to the normal insulin release and decrease patient's hypoglycemic episodes. Currently available long-acting insulin are insulin glargine 100 units (IGla 100U) and insulin detemir (IDet). However, both glargine and detemir still do not completely mimic physiological secretion.When administer high dose, their pharmacokinetic profile showed a peak concentration and a low dose may not enough to cover a 24 hours duration of action and there is still intraindividual variability. IGla 300U was a new basal insulin which was modified from IGla 100U with slow release formulation in order to overcome the unmet needs of current basal insulin. US Food and drug administration (FDA) has given marketing authorization to IGla 300U in February, 2015. IGla 300U can be used in both type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) for basal and basal-bolus therapy. It offers efficacy and safety with less pharmacodynamic variability, intraindividual variability and duration of action over 24 hours, resulting in less hypoglycemic episodes and flexible dosing regimen. In summary, IGla 300U will be an effective treatment option as basal insulin by controlling blood glucose level, offering an advantage of few hypoglycemic events and less weight gain.